Three Genes Found To Be Linked To Gout
Editor's ChoiceMain Category: Gout
Also Included In: Genetics
Article Date: 02 Oct 2008 - 0:00 PDT
| Patient / Public: | ![]() |
4.6 (5 votes) |
| Healthcare Prof: | ![]() |
According to an article published early online and in an upcoming edition of The Lancet, researchers have gained new insights into the genetic properties of gout. Dr Caroline Fox (National Heart Lung and Blood Institute, Bethesda, MD, USA) and colleagues demonstrate that three genes are linked to an increased risk of gout. Well before onset of clinical symptoms, doctors can analyze a genetic risk score based on these genes to find those at highest risk of the condition. This information can aid in developing early, targeted, and/or new treatments.
Gout is one of the most common forms of arthritis and is caused by a buildup of uric acid. When the bloodstream contains elevated concentrations of uric acid, monosodium urate (uric acid crystals) is deposited on the cartilage of joints, tendons, and surrounding tissues. The result is an inflammatory reaction in these tissues.
Dr Fox and colleagues studied the genetic factors behind gout by using data on 7,699 participants in the Framingham Heart Study and 4,148 participants in the Rotterdam Study. Researchers used genetic analysis to find out which genes were associated with a gout biomarker called serum uric acid. The results were then replicated in 11,024 white and 3,843 black participants who were part of the Atherosclerosis Risk in Communities (ARIC) study.
The gene SCLA29, involved in urate transport in the kidney, and the genes ABCG2 and SLC17A3 (also likely to be kidney urate transporters) were found to be associated with gout. Gout risk was determined using an additive genetic risk score of these high-risk alleles, and the analysis revealed graded associations with uric acid levels in all three cohorts. For example, a person with more at-risk alleles has higher uric acid levels and thus a higher risk of gout. About 2 to 13% in the Framingham cohort, 2 to 8% in the Rotterdam cohort, and 1 to 18% of white participants in the ARIC study had gout.
"Our genetic risk score was associated with up to 40-fold increased risk of developing gout, which is substantially higher than that for environmental risk factors, suggesting that knowledge of genotype could help to identify individuals at risk of developing gout long before onset of clinical features of the disease. This result underscores the value of a single assessment of the genetic risk score, whereas the measurement of uric acid concentration depends on measurement error and physiological variation over time," write the researchers.
"In addition to risk prediction, knowledge of an individual's genotype or risk score could be used to help guide clinical decisions, especially with respect to selection of drugs that are known to increase uric acid concentration and worsen gout. At present, prophylaxis for asymptomatic hyperuricaemia [increased levels of serum uric acid] is not recommended, but our genetic risk score could be used to identify individuals in which asymptomatic hyperuricaemia should be treated...The genes identified in our study could be useful for the ascertainment of novel proteins and molecular mechanisms that affect uric acid concentration, and for novel drug targets to improve treatment of gout," they conclude.
Dr Martin Aringer and Dr Juergen Graessler (University Clinical Centre Carl Gustav Carus, Dresden, Germany) write in an accompanying comment that: "Enhanced understanding of pathophysiological mechanisms might lead to improved drugs, with reduced potential for side-effects compared with today's uricosurics [drugs to treat increased serum levels of uric acid]...Even more exciting is the idea that responding to the defects of these transporter proteins might have further beneficial effects, because they could also transport other molecules besides urate."
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study
Abbas Dehghan, Anna Köttgen, Qiong Yang, Shih-Jen Hwang, W H Linda Kao, Fernando Rivadeneira, Eric Boerwinkle, Daniel Levy, Albert Hofman, Brad C Astor, Emelia J Benjamin, Cornelia M van Duijn, Jacqueline C Witteman, Josef Coresh, Caroline S Fox
The Lancet (2008).
DOI:10.1016/S0140-6736(08)61343-4
Click Here to View Journal Website
Written by: Peter M Crosta
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/articles/123765.php>
APA
http://www.medicalnewstoday.com/articles/123765.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




